Runge S, Dietz R, Haverkamp W
Medizinische Klinik Schwerpunkt Kardiologie, Campus Virchow-Klinikum und Campus Berlin-Buch, Berlin.
Dtsch Med Wochenschr. 2008 Dec;133(49):2572-8. doi: 10.1055/s-0028-1105856. Epub 2008 Nov 27.
Atrial fibrillation is the most frequent cardiac arrthythmia in adults and its prevalence is increasing with age. Therefore, the importance of an adequate therapy is an increasing challenge, in particular considering the demographic shift towards an aging population. Current antiarrhythmic drug therapies for the conversion of atrial fibrillation and the maintenance of sinus rhythm are limited by efficacy, tolerance and safety of the currently available agents. Therefore, a primary goal is to develop effective antiarrhythmic drugs with as little as possible side effects. The following review describes new promising drug therapy approaches to atrial fibrillation that may overcome some of the limitations of current therapies.
心房颤动是成年人中最常见的心律失常,其患病率随年龄增长而增加。因此,充分治疗的重要性正成为一项日益严峻的挑战,尤其是考虑到人口结构向老龄化转变的情况。目前用于房颤转复和窦性心律维持的抗心律失常药物治疗受到现有药物疗效、耐受性和安全性的限制。因此,主要目标是开发副作用尽可能少的有效抗心律失常药物。以下综述介绍了一些有望用于治疗心房颤动的新药物疗法,这些疗法可能会克服当前疗法的一些局限性。